Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate monotherapy versus triple DMARD therapy in newly diagnosed juvenile idiopathic arthritis
NL-OMON29408Not yet recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jun 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of methotrexate, 5-aminosalicylic acid + sulphasalazine, hydroxychloroquine and prednisolone in juvenile idiopathic arthritis (JIA) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Inactive disease at 6 months. Planned start Jun 2016; status: not yet recruiting.
02
Drugs
methotrexate5-aminosalicylic acid + sulphasalazinehydroxychloroquineprednisolone
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NL-OMON29408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29408.